<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119582">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546155</url>
  </required_header>
  <id_info>
    <org_study_id>2011P0022171</org_study_id>
    <nct_id>NCT01546155</nct_id>
  </id_info>
  <brief_title>The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials</brief_title>
  <official_title>The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy volunteers aged 21 to 50 are needed for a research study investigating whether pain
      will alter the binding properties of ([11C]diprenorphine), a molecule that can be used
      during brain imaging. Positron Emission Tomography (PET) and functional Magnetic Resonance
      (fMRI) imaging will be used in this study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET/MRI brain activation</measure>
    <time_frame>one day</time_frame>
    <description>This is a pilot study to help inform future research.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET imaging</intervention_name>
    <description>Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer</description>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female adults, 21 to 50 years of age

          -  No contraindications to fMRI and PET scanning

          -  Within 15% of ideal body mass index (BMI)

        Exclusion Criteria:

          -  Current significant medical, neurological, or psychiatric illness as assessed by the
             Physician Investigators

          -  Women who are pregnant or breast feeding, have gone through menopause, and/or have
             irregular menstrual cycles

          -  Claustrophobia

          -  History of head trauma

          -  Instability of responses to experimental pain (See Study Procedure Section Part II)

          -  History of asthma

          -  Use of psychotropic drugs or hormone treatments (including hormonal birth control)
             within one year of date of consent

          -  History of smoking

          -  Routine exercise in excess of one hour per day and/or three times per week

          -  Non-fluent English speaker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Kong, MD (equiv), MS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 6, 2015</lastchanged_date>
  <firstreceived_date>February 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jian Kong</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
